Inclusion of Extended Half Life Clotting Factor Products in National Blood Arrangements
The Jurisdictional Blood Committee (JBC) recently approved the inclusion of Extended Half-Life (EHL) recombinant Factor VIII and EHL Factor IX products within the national arrangements for funding and supply of blood products managed by the National Blood Authority (NBA).
The JBC decision was supported by an assessment of EHL recombinant factor VIII and factor IX products undertaken by the Medical Services Advisory Committee (MSAC). A Public Summary Document summarising the MSAC assessment and recommendations can be found at http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1511-public.
On the basis of the JBC approval, the NBA will include EHL Factor VIII and Factor IX products in the next national tender for clotting factors and related products, currently planned for 2019. Further details of this tender will be provided in due course.
In the meantime, the limited interim arrangements for EHL clotting factor products which provide temporary access to EHL products for approximately 200 haemophilia patients with high priority needs will continue. Further information about the limited interim arrangements can be found at https://www.blood.gov.au/plasma-and-recombinant-product-procurement.